From: Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
Mono sensitized patients
Double sensitized patients
Total cohort
All
Subgroup*
Tolerated field sting
156 (94.0%)
212 (92.2%)
73 (89.0%)
368 (92.9%)
Relapse
10 (6.0%)
18 (7.8%)1
9 (11.0%)2
28 (7.1%)
Sum
166 (100%)
230 (100%)
82 (100%)
396 (100%)